Revance Therapeutics, Inc. (NASDAQ: RVNC) had its "equal weight" rating re-affirmed by analysts at Barclays PLC. They now have a $7.00 price target on the stock, down previously from $10....
Revance Therapeutics, Inc. (RVNC)
Last revance therapeutics, inc. earnings: 2/24 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.revance.com
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
RVNC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RVNC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RVNC alerts
High impacting Revance Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
RVNC
News
- Revance Therapeutics, Inc. (NASDAQ: RVNC) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.MarketBeat
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Revance Therapeutics, Inc. - RVNCAccesswire
- Revance Therapeutics, Inc. (NASDAQ: RVNC) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $6.60 price target on the stock.MarketBeat
- Revance Stock - Investors of Revance Therapeutics Inc. Encouraged to Contact Kehoe Law Firm, P.C. - RVNCAccesswire
- Levi & Korsinsky Reminds Shareholders of an Investigation into Revance Therapeutics, Inc. (RVNC) Regarding Potential Securities Fraud AllegationsAccesswire
RVNC
Earnings
- 8/8/24 - Beat
RVNC
Sec Filings
- 11/7/24 - Form 10-Q
- 11/7/24 - Form 8-K
- 11/1/24 - Form 8-K
- RVNC's page on the SEC website